Seven Seas Cruises 'B' Rating Outlook Revised To Stable From Negative Aug 10

  • ID: 1793844
  • August 2010
  • Standard & Poors
1 of 3

We believe it is likely that U.S.-based cruise line operator Seven Seas' affiliate, Oceania Cruises, will maintain an adequate cushion under its 7.0x credit facility leverage covenant. We are revising our 'B' rating outlook for Seven Seas to stable from negative. The stable outlook reflects our belief that booking trends have improved sufficiently to enable credit measures to remain appropriate for the 'B' rating over the intermediate term. NEW YORK (Standard & Poor's) Aug. 5, 2010--Standard & Poor's Ratings Services today revised its rating outlook for Fort Lauderdale, Fla.-based Seven Seas Cruises S. DE R.L. to stable from negative and affirmed all ratings on the company, including the 'B' corporate credit rating. "The outlook revision to stable reflects our belief...

Companies mentioned in this report are: Seven Seas Cruises S DE R.L.
Action: Affirmed
Action: Outlook: Stable

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Seven Seas Cruises S DE R.L.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.